Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2) Article (Web of Science)

cited authors

  • Spigel, David; Jotte, Robert; Nemunaitis, John; Shum, Merrill; Schneider, Jeffrey; Goldschmidt, Jerome; Eisenstein, Jennifer; Berz, David; Seneviratne, Lasika; Socoteanu, Matei; Bhanderi, Viralkumar; Konduri, Kartik; Xia, Meng; Wang, Hong; Hozak, Rebecca R.; Gueorguieva, Ivelina; Ferry, David; Gandhi, Leena; Chao, Bo H.; Rybkin, Igor

publication date

  • February 1, 2021

webpage

published in

category

keywords

  • Interleukin (IL)-10
  • Nivolumab
  • Non-small cell lung cancer
  • Pegilodecakin
  • Pembrolizumab

start page

  • 327

end page

  • 333

volume

  • 16

issue

  • 2